Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

por Isakoff, S J, Wang, D, Campone, M, Calles, A, Leip, E, Turnbull, K, Bardy-Bouxin, N, Duvillié, L, Calvo, E
Publicado 2014

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022